Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Q: What is the exercise price of the Iovance (IOVA) inducement options granted on January 15, 2026?

Each option has an exercise price of $2.22, equal to the closing price of Iovance common stock on the Date of Grant.

Q: How do the Iovance (IOVA) inducement stock options vest?

Options vest over three years: one-third on the first anniversary of the employee’s start date and the rest in eight quarterly installments over the next two years, subject to continued employment.

Q: Under which plan were the Iovance (IOVA) inducement awards granted?

The awards were issued under the Amended and Restated 2021 Inducement Plan, as amended, and approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Q: Where can investors find the vesting start date for an individual Iovance (IOVA) inducement grant?

The First Vesting Date for each grant is the first anniversary of that employee’s start date, with subsequent quarterly vesting over the next two years.

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on January 15, 2026 covering an aggregate of 97,710 shares to 17 new non-executive employees under the Amended and Restated 2021 Inducement Plan.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on January 15, 2026 covering an aggregate of 97,710 shares to 17 new non-executive employees under the Amended and Restated 2021 Inducement Plan.

Each option has an exercise price of $2.22 (the closing price on the Date of Grant) and vests over three years: one-third on the first anniversary of each employee’s start date and the remainder in eight quarterly installments over the following two years, subject to continued employment.

Argus Jan 20 session

+3.39% close to close Open Argus

Details

News Market Reaction – IOVA

On Jan 20, the first trading day after this news, IOVA closed 3.39% above the previous close.

Data tracked by StockTitan Argus for the Jan 20 session.

Key Figures

Inducement options granted: 97,710 shares New employees: 17 employees Option exercise price: $2.22 +4 more

Inducement options granted: 97,710 shares; Aggregate stock options to 17 new non-executive employees on Jan 15, 2026
New employees: 17 employees; Recipients of inducement stock options on the Date of Grant
Option exercise price: $2.22; Closing price of Iovance common stock on Jan 15, 2026 (Date of Grant)
Plan adoption date: September 22, 2021; Original adoption of Amended and Restated 2021 Inducement Plan
Plan amendment dates: Jan 12 2022; Mar 13 2023; Feb 26 2024; Nov 22 2024; Subsequent amendments and restatements of the inducement plan
Vesting period: 3 years; One-third at first anniversary, remainder in eight quarterly installments
Quarterly installments: 8 installments; Over two years following the first vesting date, subject to employment

Historical Context

5 past events · Latest: Dec 19

5 events

Dec 19
Inducement grants

24h Move

+12.1%

Announced 43,150-share inducement stock options to four new employees.
Nov 21
Inducement grants

24h Move

+11.6%

Approved 164,900 inducement options for 11 new non-executive employees.
Nov 06
Earnings and update

24h Move

+27.6%

Q3 2025 revenue growth, guidance reaffirmation, and pipeline/commercial updates.
Nov 03
Clinical data

24h Move

-1.0%

Reported favorable Phase 2 lifileucel data in advanced nonsquamous NSCLC.
Oct 23
Earnings scheduling

24h Move

+2.7%

Announced date and webcast details for Q3 2025 results and updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tumor infiltrating lymphocyte, inducement stock options, nasdaq listing rule 5635(c)(4)

3 terms

tumor infiltrating lymphocyte medical

"novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer"

Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.

inducement stock options financial

"approved the grant of inducement stock options covering an aggregate of 97,710 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/16/2026 - 05:15 PM EST

SAN CARLOS, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,710 shares of Iovance’s common stock to 17 new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2023, February 26, 2024, and November 22, 2024, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $2.22, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Iovance (IOVA) announce about inducement stock option grants on January 15, 2026?

Iovance granted inducement stock options for an aggregate of 97,710 shares to 17 new non-executive employees under its 2021 Inducement Plan.

What is the exercise price of the Iovance (IOVA) inducement options granted on January 15, 2026?

Each option has an exercise price of $2.22, equal to the closing price of Iovance common stock on the Date of Grant.

How do the Iovance (IOVA) inducement stock options vest?

Options vest over three years: one-third on the first anniversary of the employee’s start date and the rest in eight quarterly installments over the next two years, subject to continued employment.

Under which plan were the Iovance (IOVA) inducement awards granted?

The awards were issued under the Amended and Restated 2021 Inducement Plan, as amended, and approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement option grants from Iovance (IOVA) on January 15, 2026?

17 new, non-executive employees received inducement stock option grants totaling 97,710 shares.

Where can investors find the vesting start date for an individual Iovance (IOVA) inducement grant?

The First Vesting Date for each grant is the first anniversary of that employee’s start date, with subsequent quarterly vesting over the next two years.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)